{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:00:06Z","timestamp":1782979206826,"version":"3.54.5"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Rhinology"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p>\n                    This multicenter, double-blind, placebo-controlled trial evaluated the efficacy and safety of levocabastine nasal spray, a potent and selective H\n                    <jats:sub>1<\/jats:sub>\n                    -receptor antagonist, in the control of histamine-mediated symptoms of seasonal allergic rhinitis. Adults with \u22652 year history of allergic rhinitis due to Mountain Cedar were randomized to treatment with levocabastine nasal spray (0.2 mg twice daily) or placebo for 28 days during the 1994\u20131995 Mountain Cedar allergy season. Patients assessed the severity of their rhinitis symptoms on a four-point scale twice daily. At the end of the trial, patients also performed a global evaluation of treatment efficacy on a five-point scale. Overall for the 4-week treatment period, levocabastine nasal spray significantly reduced major nasal (runny nose and sneezing) and primary rhinitis (runny nose, sneezing, and itchy\/gritty eyes) symptoms compared with placebo on both repeated measures (p = 0.023; p = 0.01) and ANOVA (p = 0.003; p &lt; 0.001) analyses. Global evaluations of treatment efficacy at the end of the trial significantly favored levocabastine over placebo (p = 0.002). Overall, the incidence of adverse events was similar for both treatment groups. In general, most adverse events were mild in intensity, with sinusitis (17% each group), headache (17% placebo, 14% levocabastine), and rhinitis (8% placebo, 2% levocabastine) most commonly reported. Levocabastine nasal spray 0.2 mg twice daily was significantly more effective than placebo in the relief of histamine-mediated symptoms in patients with seasonal allergic rhinitis and was well tolerated over the 28-day treatment period.\n                  <\/jats:p>","DOI":"10.2500\/105065899781389867","type":"journal-article","created":{"date-parts":[[2007,7,29]],"date-time":"2007-07-29T19:53:24Z","timestamp":1185738804000},"page":"55-62","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis"],"prefix":"10.1177","volume":"13","author":[{"suffix":"Jr","given":"Frank C.","family":"Hampel","sequence":"first","affiliation":[{"name":"Central Texas Health Research, New Braunfels, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Martin","sequence":"additional","affiliation":[{"name":"Southwest Allergy and Asthma Center, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jale","family":"Dolen","sequence":"additional","affiliation":[{"name":"San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Travers","sequence":"additional","affiliation":[{"name":"Janssen Research Foundation, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Karcher","sequence":"additional","affiliation":[{"name":"Janssen Research Foundation, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Holton","sequence":"additional","affiliation":[{"name":"Janssen Research Foundation, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[1999,1,1]]},"reference":[{"key":"bibr1-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30326-1"},{"key":"bibr2-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109193251206"},{"key":"bibr3-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb01103.x"},{"key":"bibr4-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90166-2"},{"key":"bibr5-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1007\/BF01990945"},{"key":"bibr6-105065899781389867","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550060-00009"},{"key":"bibr7-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1986.011.10.51907"},{"key":"bibr8-105065899781389867","first-page":"27","volume-title":"Rhinoconjunctivitis: New perspectives in topical treatment of seasonal allergic rhinitis. Proceedings of the XIIIth International Congress of Allergology and Clinical Immunology, October 1988.","author":"Van Wauwe J.P.","year":"1989"},{"key":"bibr9-105065899781389867","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529040-00002"},{"key":"bibr10-105065899781389867","first-page":"25","volume":"8","author":"Palma-Carlos A.G.","year":"1988","journal-title":"Inl J Clin Pharmacol Res"},{"key":"bibr11-105065899781389867","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)81233-4"},{"key":"bibr12-105065899781389867","doi-asserted-by":"publisher","DOI":"10.2500\/105065893781976474"},{"key":"bibr13-105065899781389867","first-page":"121","volume":"33","author":"Dahl R.","year":"1995","journal-title":"Rhinology"},{"key":"bibr14-105065899781389867","first-page":"75","volume":"67","author":"Rombaut N.","year":"1991","journal-title":"Ann Allergy"},{"key":"bibr15-105065899781389867","author":"Hassell A.E.","year":"1996","journal-title":"Effect of erythromycin on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine."},{"key":"bibr16-105065899781389867","author":"Hassell A.E.","year":"1996","journal-title":"Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine."}],"container-title":["American Journal of Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2500\/105065899781389867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2500\/105065899781389867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:34:07Z","timestamp":1777368847000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2500\/105065899781389867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.2500\/105065899781389867"],"URL":"https:\/\/doi.org\/10.2500\/105065899781389867","relation":{},"ISSN":["1050-6586","1539-6290"],"issn-type":[{"value":"1050-6586","type":"print"},{"value":"1539-6290","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}